Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spotlight: Zolbetuximab + mFOLFOX6 in Advanced Gastric or GEJ Adenocarcinoma
NCT03504397Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2018
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Jun 2018; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03504397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504397.